Source:http://linkedlifedata.com/resource/pubmed/id/16842528
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2006-7-17
|
pubmed:abstractText |
We have conducted a direct comparison of the outcomes of reduced intensity and myeloablative conditioning in younger adults with hematological malignancies<50 yr. One hundred and five patients received transplants from human leukocyte antigen (HLA)-matched donors, via either reduced intensity (n=35) or myeloablative conditioning (n=70). The median ages of the reduced intensity and myeloablative groups were 36 and 33 yr (p=0.014). Neutrophil engraftment (i.e. time to absolute neutrophil count>0.5x10(9)/L) occurred more rapidly in the reduced intensity group (median: 10 d; range: 0-21 d) than in the myeloablative group (median: 18 d; range: 11-38 d; p<0.0001). The incidence of grades 2-4 acute graft-vs.-host disease were similar between the reduced intensity and myeloablative groups, at 17% vs. 24% respectively (p=0.40). The cumulative incidence of day 100 non-relapse mortality was 18% in the reduced intensity group, and 21% in the myeloablative group (p=0.88). The overall two-yr survival rates were 43% in the reduced intensity group, and 35% in the myeloablative group (p=0.72). In conclusion, reduced intensity transplantation yielded outcomes comparable with those of myeloablative transplantation in patients under 50 with hematological malignancies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0902-0063
|
pubmed:author |
pubmed-author:CaliòF GFG,
pubmed-author:HanKyou-SupKS,
pubmed-author:KeamBhumsukB,
pubmed-author:KimByoung KookBK,
pubmed-author:KimHoon-GuHG,
pubmed-author:KimInhoI,
pubmed-author:KimTae MinTM,
pubmed-author:LeeKyung-HunKH,
pubmed-author:OhMyoung-DonMD,
pubmed-author:ParkMyoung HeeMH,
pubmed-author:ParkSeonyangS,
pubmed-author:YoonSung SooSS
|
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
496-503
|
pubmed:meshHeading |
pubmed-meshheading:16842528-Adult,
pubmed-meshheading:16842528-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16842528-Female,
pubmed-meshheading:16842528-Graft vs Host Disease,
pubmed-meshheading:16842528-Hematologic Neoplasms,
pubmed-meshheading:16842528-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16842528-Histocompatibility Testing,
pubmed-meshheading:16842528-Humans,
pubmed-meshheading:16842528-Male,
pubmed-meshheading:16842528-Melphalan,
pubmed-meshheading:16842528-Middle Aged,
pubmed-meshheading:16842528-Survival Analysis,
pubmed-meshheading:16842528-Transplantation, Homologous,
pubmed-meshheading:16842528-Transplantation Conditioning,
pubmed-meshheading:16842528-Treatment Outcome
|
pubmed:articleTitle |
Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.
|
pubmed:affiliation |
Department of Internal Medicine, Seoul National University, College of Medicine, Seoul, Korea.
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial
|